Outset Medical, Inc. (NASDAQ:OM – Get Free Report) CFO Renee Gaeta sold 4,498 shares of Outset Medical stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $3.67, for a total transaction of $16,507.66. Following the transaction, the chief financial officer directly owned 176,342 shares in the company, valued at $647,175.14. This represents a 2.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Outset Medical Stock Performance
OM opened at $2.91 on Friday. The firm has a market cap of $54.91 million, a P/E ratio of -0.75 and a beta of 1.93. Outset Medical, Inc. has a 1-year low of $2.84 and a 1-year high of $6.49. The company has a 50 day simple moving average of $3.73 and a two-hundred day simple moving average of $4.07. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.86 and a quick ratio of 3.85.
Outset Medical (NASDAQ:OM – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.01. Outset Medical had a negative net margin of 58.33% and a negative return on equity of 66.98%. The firm had revenue of $33.60 million for the quarter, compared to the consensus estimate of $31.40 million. Equities analysts forecast that Outset Medical, Inc. will post -3.51 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
OM has been the subject of a number of analyst reports. Wall Street Zen upgraded Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Wednesday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.00.
Check Out Our Latest Stock Analysis on OM
Hedge Funds Weigh In On Outset Medical
Hedge funds have recently modified their holdings of the stock. Marshall Wace LLP grew its stake in Outset Medical by 128.0% during the third quarter. Marshall Wace LLP now owns 483,380 shares of the company’s stock valued at $1,450,000 after acquiring an additional 271,387 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Outset Medical by 391.3% in the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after acquiring an additional 176,870 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Outset Medical by 4.1% in the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock valued at $239,000 after acquiring an additional 2,435 shares during the last quarter. Marquette Asset Management LLC purchased a new stake in Outset Medical in the 2nd quarter worth $212,000. Finally, Sei Investments Co. lifted its stake in Outset Medical by 15.5% in the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock worth $136,000 after purchasing an additional 4,738 shares in the last quarter.
Outset Medical Company Profile
Outset Medical is a medical technology company that develops and sells products for hemodialysis, a treatment that filters waste and excess fluid from the blood. Its main product is the Tablo Hemodialysis System, an integrated dialysis platform designed for use in hospitals, clinics and home settings. Tablo combines dialysis equipment with water purification and a touchscreen interface, aiming to simplify treatment setup and operation. The system also supports access to treatment data through connected software tools.
Read More
- Five stocks we like better than Outset Medical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.
